Reduction of left ventricular hypertrophy by Sirolimus in kidney transplant recipients: a nonrandomized clinical trial

Background: Persistence of left ventricular hypertrophy (LVH) in renal transplant recipients is associated with unfavorable outcomes. Calcineurin-inhibitor (CNI) nephrotoxicity is a major cause of morbidity and mortality after kidney transplantation. In this study we compared sirolimus (SRL) with ca...

Full description

Bibliographic Details
Main Authors: Sedghipour M, Tabatabaei SAH, Sadadi F, Kamal Hedayat D, Nikdoost F, Sate H, Ghorbani Yekta B
Format: Article
Language:fas
Published: Tehran University of Medical Sciences 2012-02-01
Series:Tehran University Medical Journal
Subjects:
Online Access:http://tumj.tums.ac.ir/browse.php?a_code=A-10-25-177&slc_lang=en&sid=1
id doaj-b9752ebee9644cacbfcdf87fff35554a
record_format Article
spelling doaj-b9752ebee9644cacbfcdf87fff35554a2020-11-25T00:24:19ZfasTehran University of Medical SciencesTehran University Medical Journal1683-17641735-73222012-02-016911718724Reduction of left ventricular hypertrophy by Sirolimus in kidney transplant recipients: a nonrandomized clinical trialSedghipour M0Tabatabaei SAH1Sadadi F2Kamal Hedayat D3Nikdoost F4Sate H5Ghorbani Yekta B6 Background: Persistence of left ventricular hypertrophy (LVH) in renal transplant recipients is associated with unfavorable outcomes. Calcineurin-inhibitor (CNI) nephrotoxicity is a major cause of morbidity and mortality after kidney transplantation. In this study we compared sirolimus (SRL) with calcineurin-inhibitor as primary immunosuppressants for the attenuation of left ventricular hypertrophy in renal transplantation recipients. Methods: In this prospective cohort study done in Shariati Hospital in 2010, we evaluated the effects of sirolimus and CNI on LVH of 55 renal transplant recipients. The cases (19) received sirolimus while the controls (36) received CNI while being matched for age and duration of transplantation. Data regarding blood pressure (BP), hemoglobin, serum creatinine, uric acid and lipid concentrations were assessed and changes in left ventricular (LV) mass were evaluated by echocardiography over a one-year follow-up. Results: Left ventricular mass significantly decreased (P=0.0001) in the SRL group but blood pressure did not differ between the two groups. LV mass and LV mass index both decreased significantly (P≤0.05) but the difference was not associated with changes in BP. The difference in interventricular septal thickness at end diastole (IVSD) and posterior wall diameter (PWD) were significant (P≤0.05) in the SRL group but the difference in end diastolic diameter (EDD) was not significant. Conclusion: Conversion from CNI to SRL-based immunosuppressive therapy in RTRs is safe and SRL may decrease LVH. SRL seems to be safe and improve renal function without cardiac compromise in kidney transplant recipients.http://tumj.tums.ac.ir/browse.php?a_code=A-10-25-177&slc_lang=en&sid=1Calcineurin inhibitor proteinleft ventricular hypertrophy (LVH)renal transplantationsirolimustransplant recipient
collection DOAJ
language fas
format Article
sources DOAJ
author Sedghipour M
Tabatabaei SAH
Sadadi F
Kamal Hedayat D
Nikdoost F
Sate H
Ghorbani Yekta B
spellingShingle Sedghipour M
Tabatabaei SAH
Sadadi F
Kamal Hedayat D
Nikdoost F
Sate H
Ghorbani Yekta B
Reduction of left ventricular hypertrophy by Sirolimus in kidney transplant recipients: a nonrandomized clinical trial
Tehran University Medical Journal
Calcineurin inhibitor protein
left ventricular hypertrophy (LVH)
renal transplantation
sirolimus
transplant recipient
author_facet Sedghipour M
Tabatabaei SAH
Sadadi F
Kamal Hedayat D
Nikdoost F
Sate H
Ghorbani Yekta B
author_sort Sedghipour M
title Reduction of left ventricular hypertrophy by Sirolimus in kidney transplant recipients: a nonrandomized clinical trial
title_short Reduction of left ventricular hypertrophy by Sirolimus in kidney transplant recipients: a nonrandomized clinical trial
title_full Reduction of left ventricular hypertrophy by Sirolimus in kidney transplant recipients: a nonrandomized clinical trial
title_fullStr Reduction of left ventricular hypertrophy by Sirolimus in kidney transplant recipients: a nonrandomized clinical trial
title_full_unstemmed Reduction of left ventricular hypertrophy by Sirolimus in kidney transplant recipients: a nonrandomized clinical trial
title_sort reduction of left ventricular hypertrophy by sirolimus in kidney transplant recipients: a nonrandomized clinical trial
publisher Tehran University of Medical Sciences
series Tehran University Medical Journal
issn 1683-1764
1735-7322
publishDate 2012-02-01
description Background: Persistence of left ventricular hypertrophy (LVH) in renal transplant recipients is associated with unfavorable outcomes. Calcineurin-inhibitor (CNI) nephrotoxicity is a major cause of morbidity and mortality after kidney transplantation. In this study we compared sirolimus (SRL) with calcineurin-inhibitor as primary immunosuppressants for the attenuation of left ventricular hypertrophy in renal transplantation recipients. Methods: In this prospective cohort study done in Shariati Hospital in 2010, we evaluated the effects of sirolimus and CNI on LVH of 55 renal transplant recipients. The cases (19) received sirolimus while the controls (36) received CNI while being matched for age and duration of transplantation. Data regarding blood pressure (BP), hemoglobin, serum creatinine, uric acid and lipid concentrations were assessed and changes in left ventricular (LV) mass were evaluated by echocardiography over a one-year follow-up. Results: Left ventricular mass significantly decreased (P=0.0001) in the SRL group but blood pressure did not differ between the two groups. LV mass and LV mass index both decreased significantly (P≤0.05) but the difference was not associated with changes in BP. The difference in interventricular septal thickness at end diastole (IVSD) and posterior wall diameter (PWD) were significant (P≤0.05) in the SRL group but the difference in end diastolic diameter (EDD) was not significant. Conclusion: Conversion from CNI to SRL-based immunosuppressive therapy in RTRs is safe and SRL may decrease LVH. SRL seems to be safe and improve renal function without cardiac compromise in kidney transplant recipients.
topic Calcineurin inhibitor protein
left ventricular hypertrophy (LVH)
renal transplantation
sirolimus
transplant recipient
url http://tumj.tums.ac.ir/browse.php?a_code=A-10-25-177&slc_lang=en&sid=1
work_keys_str_mv AT sedghipourm reductionofleftventricularhypertrophybysirolimusinkidneytransplantrecipientsanonrandomizedclinicaltrial
AT tabatabaeisah reductionofleftventricularhypertrophybysirolimusinkidneytransplantrecipientsanonrandomizedclinicaltrial
AT sadadif reductionofleftventricularhypertrophybysirolimusinkidneytransplantrecipientsanonrandomizedclinicaltrial
AT kamalhedayatd reductionofleftventricularhypertrophybysirolimusinkidneytransplantrecipientsanonrandomizedclinicaltrial
AT nikdoostf reductionofleftventricularhypertrophybysirolimusinkidneytransplantrecipientsanonrandomizedclinicaltrial
AT sateh reductionofleftventricularhypertrophybysirolimusinkidneytransplantrecipientsanonrandomizedclinicaltrial
AT ghorbaniyektab reductionofleftventricularhypertrophybysirolimusinkidneytransplantrecipientsanonrandomizedclinicaltrial
_version_ 1725352686221524992